Clinical Trial

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Study acronym: JOURNEY
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-10-12; most recent amendment 2025-10-13.
Trial Details
NCT Number NCT06087458
Lead Sponsor Perceive Biotherapeutics, Inc.
Conditions Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD
Enrollment 60 participants
Start Date 2023-06-21
Primary Completion 2027-06 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-10-15